Nobel Biocare study highlights benefits of Creos Xenoprotect

Nobel Biocare has announced the findings of a peer-reviewed bone augmentation study that has demonstrated the benefits of its product Creos Xenoprotect.

The resorbable non-cross-linked collagen dental membrane was evaluated in a clinical trial that aimed to assess its clinical efficacy and test its non-inferiority to a similar product from another manufacturer.

Creos Xenoprotect was shown to facilitate bone gain, supporting implant placement in dehiscence defects. It was associated with an 81 percent reduction in defect height six months following the augmentation procedure, which was marginally better than the comparator product.

No statistically significant differences in soft tissue health parameters were seen between the two groups, though there was a trend toward lower membrane exposure rates with Creos Xenoprotect.

The findings of the study were published in the medical journal Clinical Oral Implants Research and support Creos Xenoprotect as a scientific evidence-based choice for dental clinicians.

Hans Geiselhoringer, president of Nobel Biocare, said: "The excellent results reported in this clinical trial will give clinicians even greater confidence when choosing Creos Xenoprotect to treat their patients."

With over 20 years of experience within the dental market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current dental roles we have available, you can search for the latest job roles, register your details, or contact the team today.